Cantor Fitzgerald Weighs in on Zura Bio FY2026 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Zura Bio in a report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($0.63) for the year. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share.

Other equities analysts have also issued research reports about the company. Chardan Capital reduced their price objective on Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, March 26th. Oppenheimer reduced their price target on shares of Zura Bio from $19.00 to $17.00 and set an “outperform” rating on the stock in a research report on Friday, May 9th. Guggenheim restated a “buy” rating and issued a $15.00 price objective on shares of Zura Bio in a research report on Wednesday, March 26th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Zura Bio in a research note on Thursday, April 3rd. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $14.33.

Zura Bio Price Performance

NASDAQ ZURA opened at $1.28 on Wednesday. The stock’s 50 day simple moving average is $1.21 and its 200 day simple moving average is $1.65. Zura Bio has a one year low of $0.97 and a one year high of $5.07. The firm has a market cap of $87.52 million, a PE ratio of -1.83 and a beta of -0.12.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02).

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. American Century Companies Inc. bought a new stake in shares of Zura Bio during the fourth quarter worth approximately $27,000. Prudential Financial Inc. acquired a new stake in Zura Bio during the 4th quarter worth $28,000. Two Sigma Advisers LP bought a new stake in shares of Zura Bio during the 4th quarter valued at $32,000. ProShare Advisors LLC acquired a new position in shares of Zura Bio in the 4th quarter valued at $35,000. Finally, XTX Topco Ltd acquired a new position in shares of Zura Bio in the 4th quarter valued at $44,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.